Delving into the Latest Updates on Liraglutide (Chongqing Paijin) with Synapse

Primary objective: To compare the efficacy and safety of liraglutide injection and Victoza® in the treatment of patients with type 2 diabetes. Secondary objective: To compare the similarity of PK parameters of liraglutide injection and Victoza® in patients with type 2 diabetes after multiple administration.

Start Date05 Jul 2021

Sponsor / Collaborator

Chongqing Paijin Biotechnology Co Ltd.

[+1]

CTR20191362 / Completed

利拉鲁肽注射液在健康受试者中的随机、开放、两周期、单次给药、双交叉临床比对试验

[Translation] A randomized, open-label, two-period, single-dose, double-crossover clinical comparative study of liraglutide injection in healthy subjects

评价重庆宸安生物制药有限公司生产的利拉鲁肽注射液与诺和诺德（中国）制药有限公司生产的利拉鲁肽注射液（商品名：诺和力）在健康受试者体内单次给药PK特征的相似性和安全性。

[Translation]

To evaluate the similarity and safety of the single-dose PK characteristics of liraglutide injection produced by Chongqing Chenan Biopharmaceutical Co., Ltd. and liraglutide injection (trade name: Victoza) produced by Novo Nordisk (China) Pharmaceuticals Co., Ltd. in healthy subjects.

Start Date03 Sep 2019

Sponsor / Collaborator

Chongqing Paijin Biotechnology Co Ltd.

[+1]

100 Clinical Results associated with Liraglutide (Chongqing Paijin)

Login to view more data

100 Translational Medicine associated with Liraglutide (Chongqing Paijin)

Login to view more data

100 Patents (Medical) associated with Liraglutide (Chongqing Paijin)

Login to view more data

2

Literatures (Medical) associated with Liraglutide (Chongqing Paijin)

01 Aug 2010·Der InternistQ4 · MEDICINE

NN8022-1807-Studie

Q4 · MEDICINE

Article

Author: W.A. Scherbaum ; S. Nitschmann

Nutrición HospitalariaQ4 · MEDICINE

Tratamiento de obesidad con liraglutide en un paciente con Síndrome de Prader-Willi: reporte de caso

Q4 · MEDICINE

ArticleOA

Author: Mario Antonio Molina-Ayala ; Aldo Ferreira-Hermosillo ; Diego Andrés Cadena-Obando

100 Deals associated with Liraglutide (Chongqing Paijin)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	CN	Chongqing Chenan Biopharmaceutical Co., Ltd.	05 Jul 2021
Diabetes Mellitus, Type 2	Phase 3	CN	Chongqing Paijin Biotechnology Co Ltd.	05 Jul 2021